Mass action kinetic analysis of multidrug resistance transporters expressed in confluent cell monolayers

The Structure of Biological Membranes: Third Edition

Volumn , Issue , 2011, Pages 241-272

  Lumen, Annie Albin ^a   Silverman, Deborah ^a   Martinez, Esteban ^a   Ahmed, Zeba ^a   Agnani, Deep ^a   Acharya, Poulomi ^a   Bentz, Joe ^a  

^a DREXEL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861092832     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (122)

1. Abe T, Masayuki K, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, and Yawo H (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 24: 17159-17163
2. Acharya P, Polli JW, Ayrton A, Ellens H, and Bentz J (2008) Kinetic identification of membrane transporters that assist P-gp mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. Drug Metab. Dispos. 36: 452-460
3. Acharya P, Tran TT, Polli JW, Ayrton A, Ellens H, and Bentz J (2006) P-glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites. Biochemistry 45: 15505-15519
4. Abreu MS, Estronca LM, Moreno MJ, and Vaz WL (2003) Binding of a fluorescent lipid amphiphile to albumin and its transfer to lipid bilayer membranes. Biophys. J. 84: 386-399
5. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T et al. (2003) Molecular characterization of human and rat organic anion transporter OATP-D. Am. J. Physiol. Renal Physiol. 285:1188-1197
6. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, and Chang G (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1719-1722
7. Al-Shawi MK, Polar MK, Omote H, and Figler RA (2003) Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J. Biol. Chem. 278: 52629-52640
8. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmaco-logical aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39: 361-398
9. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, and Gottesman MM (2003) P-glycoprotein: From genomics to mechanism. Oncogene 22: 7468-7485
10. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, and Pastan, I (1992) Partial purification and reconstitution of the human multidrug-resistance pump: Characterization of the drug-stimulatable ATP hydrolysis. Proc. Natl. Acad. Sci. U. S. A. 89: 8472-8476
11. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, Wunderli-Allenspach H, Merkle HP, and Langguth P (1998) P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: The influence of culturing conditions and drug exposure on P-gp expression levels. J. Pharm. Sci. 87: 757-762
12. Bentz J, Tran TT, Polli JW, Ayrton A, and Ellens H (2005) The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. Pharm. Res. 22: 1667-1677
13. Biedler JL and Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic and cytogenetic studies. Cancer Res. 30: 1174-1184
14. Borgnia MJ, Eytan GD, and Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J. Biol. Chem. 271: 3163-3171
15. Butor C and Davoust J (1992) Apical to basolateral surface area ratio and polarity of MDCK cells grown on different supports. Exp. Cell. Res. 203(1): 115-127
16. Chang JH and Benet LZ (2005) Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells. Mol. Pharm. 2: 428-434
17. Cheng Y and Prusoff WH (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108
18. Choo EF, Kurnik D, Muszkat M, Ohkubo T, Shay SD, Higginbotham JN, Glaeser H, Kim RB, Wood AJ, and Wilkinson GR (2006) Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J. Pharmacol. Exp. Ther. 317: 1012-1018
19. Collett A, Tanianis-Hughes J, Hallifax D, and Warhurst G (2004) Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm. Res. 21:819-826
20. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27: 866-871
21. Dano K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochem. Biophys. Acta 323: 466-483
22. Dhir R and Gros P (1992) Functional analysis of chimeric proteins constructed by exchanging homologous domains of two P-glycoproteins conferring distinct drug resistance profiles. Biochemistry 31: 6103-6110
23. Döppenschmitt S, Spahn-Langguth H, Regårdh CG, and Langguth P (1999) Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 88: 1067-1072
24. Epel D (2003). Protection of DNA during early development: Adaptations and evolutionary consequences. Evol. Dev. 5(1): 83-88
25. Epel D, Cole B, Hamdoun A, and Thurber RV. (2006) The sea urchin embryo as a model for studying efflux transporters: Roles and energy cost. Mar. Environ. Res. 62: S1-S4
26. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, and Borst P (2000) Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 P-gp-, MRP1-and MRP2-mediated transport. Br. J. Cancer 83: 366-374
27. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, and Pastan I (1987) Expression pattern of MDR mRNA in human tumors and tissues. Proc. Natl. Acad. Sci. U.S.A. 84: 265-269
28. Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, Onogawa T et al. (2001) Identification of thyroid hormone transporters in humans: Different molecules are involved in a tissue-specific manner. Endocrinology 142: 2005-2012
29. Gao J, Murase O, Schowen RL, Aubé J, Borchardt RT (2001) A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm. Res. 18: 171-176
30. Gao B, Huber RD, Wenzel A, Vavricka SR, Ismair MG, Remé C, and Meier PJ. (2005). Localization of organic anion transporting polypeptides in the rat and human ciliary body epithelium. Exp. Eye Res. 80: 61-72
31. Glavinas H, Méhn D, Jani M, Oosterhuis B, Herédi-Szabó K, and Krajcsi P (2008) Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. Expert Opin. Drug Metab. Toxicol. 4: 721-732
32. Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland WC, and Friedberg T (2002) Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem. Pharmacol. 64: 1569-1578
33. Gottesman MM, Ambudkar SV, and Xia D (2009) Structure of a multidrug transporter. Nat. Biotechnol. 27: 546-547
34. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62: 385-427
35. Hah JS, Ryu J, Lee W, Jung CY, Lachaal M, and Spangler RA (2002) The hepatocyte glucose-6-phosphatase subcomponent T3: Its relationship to GLUT2. Biochim. Biophys. Acta 1564: 198-206
36. Hagenbuch B and Meier PJ (1994) Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J. Clin. Invest. 93: 1326-1331
37. Hansson GC, Simons K, and van Meer G (1986) Two strains of the Madin-Darby canine kidney (MDCK) cell line have distinct glycosphingolipid compositions. EMBO J. 5(3): 483-489
38. Higgins CF and Gottesman MM (1992) Is the multidrug transporter a flippase? Trends Biochem. Sci. 17: 18-21
39. Higgins CF, Hiles ID, Whalley K, and Jamieson DJ (1985) Nucleotide binding by membrane components of bacterial periplasmic binding protein-dependent transport systems. EMBO J. 4: 1033-1039
40. Hinterdorfer P, Gruber HJ, Striessnig J, Glossmann H, and Schindler H (1997) Analysis of membrane protein self-association in lipid systems by fluorescence particle counting: Application to the dihydropyridine receptor. Biochemistry 36: 4497-4504
41. Ho NFH, Burton PS, Conradi RA, and Barsuhn CL. 1995. A biophysical model of passive and polarized active transport processes in Caco-2 cells: Approaches to uncoupling apical and basolateral membrane events in the intact cell. J. Pharm. Sci. 84(1): 21-27
42. Ho NFH, Raub TJ, Burton PS, Bausuhn, CL, Adson A, Audus KL, and Borchardt R (2000) Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers, in Transport Processes in Pharmaceutical Systems, Amidon GL and Lee V (Eds.), pp. 219-316, Marcell Dekker, New York
43. Hosoya KI, Kim KJ, and Lee VH (1996) Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm. Res.13: 885-890
44. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, and Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274: 37161-37168
45. Huber RD, Gao B, Sidler Pfändler MA, Zhang-Fu W, Leuthold S, Hagenbuch B, Folkers G, Meier PJ, Stieger B (2007) Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am. J. Physiol. Cell Physiol. 292: 795-806
46. Inui KI, Masuda S, and Saito H (2000) Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 58: 944-958
47. Ito S, Woodland C, Sarkadi B, Hockmann G, Walker SE, and Koren G (1999) Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. Am. J. Physiol. 277: F84-96
48. Jang, SH., Wientjes MG, and Au JL-S (2003) Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular drug binding on intracellular paclitaxel pharmacokinetics: Application of computational modeling. J. Pharmacol. Exp. Therap. 304: 773-780
49. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem. Biophys. Acta 455: 152-162
50. Kessel D, Botterill V, and Woodinsky I (1968) Uptake and retention of daunomycin by mouse leukemic cells as a factor in drug response. Cancer Res. 28: 938-941
51. Kalvass JC and Pollack GM (2007) Kinetic considerations for the quantitative assessment of efflux activity and inhibition: Implications for understanding and predicting the effects of efflux inhibition. Pharm. Res. 24: 265-276
52. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, and Hall MD (2009) Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin. Pharmacol. Ther. 86: 368-377
53. Kartner N, Evernden-Porelle D, Bradley G, and Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820-823
54. Keizer J (1987) Diffusion effects on rapid bimolecular chemical reactions. Chem. Rev. 87: 167-180
55. Kullack-Ublick GA, Ismair MG, Steiger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, and Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroentology 120: 525-533
56. Kurnik D, Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJ, and Muszkat M (2008) Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. Anesthesiology 109: 1092-1099
57. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, and Schuetz JD (2000) Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol. Pharmacol. 57:24-35
58. Ling V (1975) Drug resistance and membrane alteration in mutants of mammalian cells. Can. J. Genet. Cytol. 17: 503-515
59. Ling V and Thompson LH (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J. Cell. Physiol. 83:103-116
60. Litman T, Nielsen D, Skovsgaard T, Zeuthen T, and Stein WD (1997) ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines. Biochim. Biophys. Acta 1361: 147-158
61. Litman T, Skovsgaard T, and Stein WD (2003) Pumping of drugs by P-glycoprotein: A two-step process? J. Pharmacol. Exp. Ther. 307: 846-853
62. Liu R and Sharom FJ (1998) Proximity of the nucleotide binding domains of the P-glycoprotein multidrug transporter to the membrane surface: A resonance energy transfer study. Biochemistry 37: 6503-6512
63. Loo TW, Bartlett MC, and Clarke DM (2003) Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. J. Biol. Chem. 278 (16): 13603-13606
64. Loo TW and Clarke DM (2000) Drug-stimulated ATPase activity of human P-glycoprotein is blocked by disulfide cross-linking between the nucleotide-binding sites. J. Biol. Chem. 275: 19435-19438
65. Loo TW and Clarke DM (2001) Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. J. Biol. Chem. 276: 36877-36880
66. Loo TW and Clarke DM (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol. 206: 173-185
67. Lowes S, Cavet M, and Simmons N (2003) Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur. J. Pharmacol. 458: 49-56
68. Lugo MR and Sharom FJ (2005) Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: Evidence for simultaneous binding of both drugs. Biochemistry 44: 14020-14029
69. Lumen AA, Acharya P, Polli JW, Ayrton A, Ellens H, and Bentz J (2010) If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer? Drug Metab. Dispos. 38:260-269
70. Ma JD, Tsunoda SM, Bertino JS, Trivedi M, Beale KK, and Nafziger AN (2010) Evaluation of in vivo P-glycoprotein phenotyping probes: A need for validation. Clin. Pharmacokinet. 49(4): 223-237
71. Matsushima S, Maeda K, Kondo C, Hirano M, Sasak, M, Suzuki H, and Sugiyama Y (2005) Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther. 314: 1059-1067
72. Meier-Abt F, Mokrab Y, and Mizuguchi K (2006) Organic anion transporting polypeptides of the OATP/SLCO superfamily: Identification of New members in nonmamaalian species, comparative modeling and a potential transport mode. J. Membr. Biol. 208: 213-227
73. Meyer-Almes FJ and Auer M (2000) Enzyme inhibition assays using fluorescence correlation spectroscopy: A new algorithm for the derivation of kcat/KM and Ki values at substrate concentrations much lower than the Michaelis constant. Biochemistry 39: 13261-13268
74. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, and Abe T (2004) The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet.19: 171-179
75. Mizuno N, Niwa T, Yotsumoto Y, and Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 55: 425-461
76. Molski A, Berling S, and Keizer J (1996) Rapid chemical reactions in two dimensions: Spatially nonlocal effects. J. Phys. Chem. 100:19049-19054
77. Nervi P, Li-Blatter X, Aänismaa P, and Seelig A (2010) P-glycoprotein substrate transport assessed by comparing cellular and vesicular ATPase activity. Biochim. Biophys. Acta 1798: 515-525
78. Noe B, Hagenbuch B, Steiger B, and Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. U. S. A. 94: 10346-10350
79. Nozawa T, Imai K, Nezu J, Tsuji A, and Tamai I (2004) Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. 308: 438-445
80. Pawagi AB, Wang J, Silverman M, Reithmeier RA, and Deber CM (1994) Transmembrane aromatic amino acid distribution in P-glycoprotein: A functional role in broad substrate specificity. J. Mol. Biol. 235: 554-564
81. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, and Meier PJ (2002) Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol. Endocrinol. 16: 2283-2296
82. Polli JW, Wring SA, Humphreys J, Euang L, Morgan JB, Webster LO, and Serabjit-Singh, CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299: 620-628
83. Qu Q and Sharom FJ (2001) FRET analysis indicates that the two ATPase active sites of the P-glycoprotein multidrug transporter are closely associated. Biochemistry 40: 413-422
84. Rautio J, Humphreys JE, Webster LO, Balkrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW (2006) In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug. Metab. Dispos. 34: 786-792
85. Riordan JR and Ling V (1979) Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J. Biol. Chem. 254: 12701-12705
86. Roninson IB, Chin J E, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, and Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug resistant KB carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 83: 4538-4542
87. Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, Kerr ID, Callaghan R, Schmidlin A, Wooding C, Linton KJ, and Higgins CF (2001) Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J. 20:5615-5625
88. Sahi J (2005) Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates. Expert Opin. Drug Metab. Toxicol. 1: 409-427
89. Sarkadi B, Price EM, Boucher RC, Germann UA, and Scarborough GA (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 267: 4854-4858
90. See YP, Carlsen SA, Till J E, and Ling V (1974) Increased drug permeability in Chinese hamster ovary cells in the presence of cyanide. Biochem. Biophys. Acta 373: 242-252
91. Seelig A (1998) A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251: 252-261
92. Senior AE, Al-Shawi MK, and Urbatsch IL (1995) The catalytic cycle of P-glycoprotein. FEBS Lett. 377:285-289
93. Senior AE, Sashi N, and Weber J (2000) Rate acceleration of ATP hydrolysis by F1Fo-ATP synthase, J. Exp. Biol. 203:35-40
94. Shapiro AB and Ling V (1997) Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. Eur. J. Biochem. 250: 122-129
95. Sharom FJ (1995) Characterization and functional reconstitution of the multidrug transporter. J. Bioenerg. Biomembr. 27: 15-22
96. Sharom FJ (2008) ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9(1): 105-127
97. Sharom FJ and Eckford PD (2003) Reconstitution of membrane transporters. Methods Mol. Biol. 227: 129-154
98. Spoelstra EC, Westerhoff HV, Pinedo HM, Dekker H, and Lankelma J (1994) The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur. J. Biochem. 221: 363-373
99. St. Pierre MV, Hagenbuch B, Ugele B, Meier PJ, and Stallmach T (2002) Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J. Clin. Endocrinol. Metab. 87: 1856-1863
100. Stein WD (1997) Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol. Rev. 77: 545-590
101. Su Y, Zhang X, and Sinko PJ (2004) Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 Cells. Mol. Pharm. 1: 49-56
102. Sun H and Pang KS (2008) Permeability, transport, and metabolism of solutes in Caco-2, cell monolayers: a theoretical study, Drug. Metab. Dispos. 36: 102-123
103. Tamai I, Nezu J, Uchino H, Sai U, Oku A, Shimane M, and Tsuji A (2000) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273:251-260
104. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, and Tsuji A (2001) Functional comparison of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm. Res.18: 1262-1269
105. Tang F, Horie K, and Borchardt RT (2002) Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm. Res. 19: 773-779
106. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, and Hori R (1992) Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 263: 840-845
107. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 84: 7735-7738
108. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem. 37: 159-164
109. Tran TT, Mittal A, Gales T, Maleeff B, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J (2004) Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. J Pharm Sci 93: 2108-2123
110. Tran TT, Mittal A, Aldinger T, Polli JW, Ayrton, A, Ellens H, and Bentz J (2005) The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys. J. 88: 715-38
111. Troutman MD and Thakker DR (2003a) Novel experimental parameters to quantify the modulation of absorptive and secretory transport of substrates by P-glycoprotein in cell culture models of intestinal epithelium. Pharm. Res. 220: 1210-1224
112. Troutman MD and Thakker DR (2003b) Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across caco-2 cell monolayers. Pharm. Res. 20: 1200-1209
113. Ueda K, Cardarelli C, Gottesman MM, and Pastan I (1986) Expression of a full-length cDNA for the human "MDR1" (Pglycoprotein) gene confers multidrug resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. U. S. A. 84: 3004-3008
114. Urbatsch IL, Sankaran B, Weber J, and Senior AE (1995) P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J. Biol. Chem. 270: 19383-19390
115. Urbatsch IL, Tyndall GA, Tombline G, and Senior AE (2003) P-glycoprotein catalytic mechanism: Studies of the ADP-vanadate inhibited state. J. Biol. Chem. 278: 23171-23179
116. Van der Blick AM, Van der Velde-Koerts T, Ling V, and Borst P (1986) The over-expression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line. Mol. Cell. Biol. 6: 1671-1678
117. van Veen HW, Margolles A, Müller M, Higgins CF, and Konings WN (2000) The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism. EMBO J. 19: 2503-2514
118. Vaz A and Vicente L. 2007. A particle swarm pattern search method for bound constrained global optimization. J. Glob. Optim. 39: 197-219
119. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36: 164-172
120. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo I J, and Scherman D (1994) Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 48: 1528-1530
121. Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, Goto J, Hishinuma T, and Mano N (2008) Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 260: 163-169
122. Zong J, Pollack GM (2003) Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J. Pharmacol. Exp. Ther. 306: 556-562